EAdjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

被引：207

作者：

Kris, Mark G. ^{[2
]}

Gaspar, Laurie E. ^{[5
]}

Chaft, Jamie E. ^{[2
]}

Kennedy, Erin B. ^{[1
]}

Azzoli, Christopher G. ^{[6
]}

Ellis, Peter M. ^{[10
]}

Lin, Steven H. ^{[7
]}

Pass, Harvey I. ^{[3
]}

Seth, Rahul ^{[4
]}

Shepherd, Frances A. ^{[11
]}

Spigel, David R. ^{[9
]}

Strawn, John R. ^{[8
]}

Ung, Yee C. ^{[12
]}

Weyant, Michael ^{[5
]}

机构：

[1] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA

[2] Mem Sloan Kettering Canc Ctr, Hauppauge, NY USA

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Syracuse Univ, Upstate Med Ctr, Syracuse, NY USA

[5] Univ Colorado, Sch Med, Aurora, CO USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] MD Anderson Canc Ctr, Houston, TX USA

[8] Patient Representat, Houston, TX USA

[9] Sarah Cannon Canc Ctr, Nashville, TN USA

[10] Juravinski Canc Ctr, Hamilton Hlth Sci, Hamilton, ON, Canada

[11] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Sunnybrook Reg Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 25期

关键词：

TYROSINE KINASE INHIBITORS; POSTOPERATIVE RADIOTHERAPY; INTERNATIONAL ASSOCIATION; INDEPENDENT PREDICTOR; PROGNOSTIC MARKER; POOLED ANALYSIS; BAD-NEWS; CHEMOTHERAPY; ADENOCARCINOMA; CLASSIFICATION;

D O I：

10.1200/JCO.2017.72.4401

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy. An update of these systematic reviews and a search for studies related to radiation therapy found no additional randomized controlled trials. Recommendations Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections. For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. The guideline provides information on factors other than stage to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations. Adjuvant chemotherapy is not recommended for patients with stage IA disease. Adjuvant radiation therapy is not recommended for patients with resected stage I or II disease. In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease. (C) 2017 by American Society of Clinical Oncology

引用

页码：2960 / +

页数：17

共 45 条

[1] Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review
Bradbury, Penelope
Sivajohanathan, Duvaraga
Chan, Adrien
Kulkarni, Swati
Ung, Yee
Ellis, Peter M.
CLINICAL LUNG CANCER, 2017, 18 (03) : 259 - +
[2] Resected non-small-cell lung cancer stage I/II: Indication for adjuvant/neoadjuvant therapy?
Hoffmann, H
LUNG CANCER, 2004, 45 : S91 - S97
[3] Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Wen, Miaomiao
Wang, Lei
Wang, Xuejiao
Yang, Sanhu
Sun, Ying
Xia, Jinghua
Zhang, Yanning
Zhang, Zhipei
Huang, Lijun
Jiang, Tao
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12) : 686 - 693
[4] Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Krop, Ian
Ismaila, Nofisat
Andre, Fabrice
Bast, Robert C.
Barlow, William
Collyar, Deborah E.
Hammond, M. Elizabeth
Kuderer, Nicole M.
Liu, Minetta C.
Mennel, Robert G.
Van Poznak, Catherine
Wolff, Antonio C.
Stearns, Vered
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2838 - +
[5] A phase III randomized trial of postoperative adjuvant therapy in Stage II or IIIA completely resected non-small cell lung cancer
Yoon, S
Choi, E
Kim, S
Suh, C
Lee, J
Shim, T
Kim, W
Kim, D
Park, S
Park, C
LUNG CANCER, 2005, 49 : S288 - S288
[6] Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer
Harubumi Kato
Masahiro Tsuboi
Yasufumi Kato
Norihiko Ikeda
Tetsuya Okunaka
Chikuma Hamada
International Journal of Clinical Oncology, 2005, 10 (3) : 157 - 164
[7] Operation and adjuvant therapy of non-small cell lung cancer (Stage I to operable IIIA)
Eberhardt, Wilfried
Fietkau, Rainer
Griesinger, Frank
Passlick, Bernward
Stuschke, Martin
ONKOLOGIE, 2006, 29 : 7 - 10
[8] Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations
Henry, N. Lynn
Somerfield, Mark R.
Abramson, Vandana G.
Allison, Kimberly H.
Anders, Carey K.
Chingos, Diana T.
Hurria, Arti
Openshaw, Thomas H.
Krop, Ian E.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2303 - +
[9] Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?
Sibille, Anne
Wauters, Isabelle
Vansteenkiste, Johan
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 529 - 539
[10] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer
Novello, Silvia
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 3985 - +

← 1 2 3 4 5 →